1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2, 3-dioxygenase (IDO) is an intracellular enzyme that catalyzes the transformation of L-tryptophan to N-formylkynurenine, which is the first and rate-controlling step in the kynurenine pathway.

IDO is a rate-limiting enzyme that catalyzes the degradation of tryptophan into kynurenine and is recognized to exert a tolerizing effect on T cells that require tryptophan to proliferate5. IDO also plays an important role in the activation and regulation of functionally quiescent regulatory T cells.

IDO is a heme-containing enzyme that catalyzes the oxidative cleavage of 2,3 double bond of indole ring. IDO has the ability to inhibit T-cell activation by tryptophan starvation, whereas T-cell survival and proliferation are regulated by O2 free radicals and kynurenine derivatives. IDO plays a crucial role in autoimmunity,infections and malignancies.

Indoleamine-2,3-dioxygenase (IDO) one of the most important immunoregulator enzyme responsible for metabolism of tryptophan as part of Kynurenin pathway. Tryptophan is catabolized in the tumor tissue by the rate-limiting enzyme IDO expressed in tumor cells or antigen presenting cells.

Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

  • IDO1

  • IDO2

  • IDO

Indoleamine 2,3-Dioxygenase (IDO) Related Products (27):

Cat. No. Product Name Effect Purity
  • HY-15760
    Necrostatin-1 Inhibitor 99.20%
    Necrostatin-1 (Nec-1) is a potent, selective and cell-permeable necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. It acts by inhibiting the death domain kinase RIP (RIP1) in the necroptosis pathway.
  • HY-15689
    Epacadostat Inhibitor 99.65%
    Epacadostat (INCB 024360) is a potent and selective indoleamine 2,3-dioxigenase 1 (IDO1) inhibitor with an IC50 of 71.8 nM.
  • HY-101560
    Linrodostat Inhibitor 99.92%
    Linrodostat (BMS-986205; ONO-7701) is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor.
  • HY-16724
    Indoximod Inhibitor 98.98%
    Indoximod (D-1MT, NLG8189) is an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor with a Ki of 19 μM.
  • HY-13983
    IDO-IN-7 Inhibitor 99.92%
    IDO-IN-7 (NLG-919 analogue) is a a potent IDO1 inhibitor with an IC50 of 38 nM.
  • HY-111540
    LY-3381916 Inhibitor
    LY-3381916 is a potent, selective and brain penetrated inhibitor of IDO1 activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
  • HY-112147
    IDO1 and HDAC1 Inhibitor Inhibitor
    IDO1 and HDAC1 Inhibitor (Compound 10) is a dual IDO1 and HDAC1 inhibitor with IC50s of 69.0 nM and 66.5 nM, respectively.
  • HY-128355
    IDO/TDO-IN-1 Inhibitor
    IDO/TDO-IN-1 (compound 25) is a highly potent and orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50s of 9.7 and 47 nM, respectively .
  • HY-18770B
    Navoximod Inhibitor 99.99%
    Navoximod (GDC-0919; NLG-​919) is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
  • HY-N0736
    Coptisine chloride Inhibitor 99.29%
    Coptisine chloride is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive IDO inhibitor with a Ki value of 5.8 μM and an IC50 value of 6.3 μM.
  • HY-101111
    PF-06840003 Inhibitor 99.80%
    PF-06840003 is a highly selective orally bioavailable IDO-1 inhibitor.
  • HY-18769
    IDO-IN-4 Inhibitor 99.40%
    IDO-IN-4 is an indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1.
  • HY-100687
    GNF-PF-3777 Inhibitor 99.21%
    GNF-PF-3777 (8-Nitrotryptanthrin) is a potent human indoleamine 2,3-dioxygenase 2 (hIDO2) inhibitor which significantly reduces IDO2 activity with Ki of 0.97 μM.
  • HY-112164
    IACS-8968 Inhibitor 98.13%
    IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
  • HY-15683
    IDO5L Inhibitor 99.89%
    IDO5L is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 67 nM.
  • HY-100771
    IDO-IN-2 Inhibitor 98.54%
    IDO-IN-2 is an IDO inhibitor extracted from patent WO/2015031295 A1, compound example 1, has IC50 values of 0.068 μM in HeLa cell and 0.16 μM in HEK293 cell.
  • HY-18770
    IDO-IN-5 Inhibitor 99.90%
    IDO-IN-5 (NLG-1489) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1489, has an IC50 of 1-10 μM.
  • HY-18770C
    IDO-IN-8 Inhibitor 99.99%
    IDO-IN-8 (NLG-1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1487, has an IC50 of 1-10 μM.
  • HY-16987
    IDO-IN-3 Inhibitor
    IDO-IN-3 is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 290 nM.
  • HY-18770A
    IDO-IN-6 Inhibitor 99.90%
    IDO-IN-6 (NLG-1486) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, Compound 1486, has an IC50 of <1 μM.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.